Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) is a biopharmaceutical company with an integrated drug discovery clinical development approach, anchored in Asia Pacific with a global footprint. Antengene aims to provide the most advanced anti-cancer drugs to patients in China, the Asia Pacific Region around the world. Since its official start in April 2017, Antengene has built a pipeline of 12 clinical pre-clinical stage assets, obtained 9 IND approvals has 9 ongoing cross-regional clinical trials in Asia Pacific. At Antengene, we focus on developing drug candidates with novel MoAs first-in-/best-in- potential to address significant unmet medical needs. The vision of Antengene is to "Treat Patients Beyond Borders" through research, development commercialization of first-in-/best-in- therapeutics.
内容由
提供
恭喜您，提交成功！
您的编辑正在审核中，1个工作日内，会以邮件通知您结果
提交失败。
